Upvote
Downvote
Oncology Territory Manager, Southeast
Share Job
- Suggest Revision
Full-time
- Enabled by our proprietary drug discovery platform, Deciphera has developed a diverse pipeline of wholly-owned drug candidates.
- QINLOCK (ripretinib) is Deciphera’s switch control inhibitor developed for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United States, and the United Kingdom.
- We wholly own QINLOCK and all of our drug candidates with the exception of a development and commercialization out-license agreement for QINLOCK in Greater China.
- Partnering with cross-functional commercial partners such as market access and medical teams to provide comprehensive solutions for customers.
- Becoming a true subject matter expert on all key topics that impact the success of the business – GIST and TGCT disease state knowledge, clinical acumen, product expertise, competitive intelligence, market dynamics, customer needs across segments, local market access, etc.
Active Job
Updated 18 days agoSimilar Job
Relevance
Active